Volume | 1,768,714 |
|
|||||
News | - | ||||||
Day High | 64.65 | Low High |
|||||
Day Low | 64.54 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Alpine Immune Sciences Inc | ALPN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
64.57 | 64.54 | 64.65 | 64.62 | 64.57 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
17,630 | 1,768,714 | $ 64.61 | $ 114,283,837 | - | 6.71 - 64.70 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:20:01 | formt | 1,715 | $ 64.62 | USD |
Alpine Immune Sciences (ALPN) Options Flow Summary
Alpine Immune Sciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
3.75B | 58.10M | - | 58.88M | -32.18M | -0.55 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Alpine Immune Sciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALPN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 64.42 | 64.70 | 64.40 | 64.53 | 2,508,537 | 0.20 | 0.31% |
1 Month | 38.65 | 64.70 | 34.25 | 58.21 | 4,449,028 | 25.97 | 67.19% |
3 Months | 26.84 | 64.70 | 26.09 | 49.80 | 2,250,472 | 37.78 | 140.76% |
6 Months | 8.68 | 64.70 | 8.33 | 39.35 | 1,548,074 | 55.94 | 644.47% |
1 Year | 7.16 | 64.70 | 6.71 | 35.29 | 898,275 | 57.46 | 802.51% |
3 Years | 12.25 | 64.70 | 4.82 | 30.33 | 368,382 | 52.37 | 427.51% |
5 Years | 6.50 | 64.70 | 2.05 | 26.22 | 277,836 | 58.12 | 894.15% |
Alpine Immune Sciences Description
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing innovative, protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The company's proprietary scientific platform uses a process known as directed evolution to create therapeutics capable of modulating human immune system proteins. Its product pipeline includes ALPN-101 and ALPN-202. |